Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer

Conditions:   Extrahepatic Bile Duct Adenocarcinoma, Biliary Type;   Gallbladder Adenocarcinoma, Biliary Type;   Metastatic Pancreatic Adenocarcinoma;   Recurrent Cholangiocarcinoma;   Recurrent Gallbladder Carcinoma;   Recurrent Hepatocellular Carcinoma;   Recurrent Intrahepatic Cholangioca rcinoma;   Recurrent Pancreatic Carcinoma;   Stage III Gallbladder Cancer AJCC V7;   Stage III Hepatocellular Carcinoma AJCC v7;   Stage III Intrahepatic Cholangiocarcinoma AJCC v7;   Stage III Pancreatic Cancer AJCC v6 and v7;   Stage IIIA Gallbladder Cancer AJCC  v7;   Stage IIIA Hepatocellular Carcinoma AJCC v7;   Stage IIIB Gallbladder Cancer AJCC v7;   Stage IIIB Hepatocellular Carcinoma AJCC v7;   Stage IIIC Hepatocellular Carcinoma AJCC v7;   Stage IV Gallbladder Cancer AJCC v7;   Stage IV Hepatocellular Carcinoma AJCC  v7;   Stage IV Pancreatic Cancer AJCC v6 and v7;   Stage IVA Gallbladder Cancer AJCC v7;   Stage IVA Hepatocellular Carcinoma AJCC v7;   Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7;   Stage IVB Gallbladder Cancer AJCC v7;   Stage IVB Hepatocellular Carcino ma AJCC v7;   Stage IVB Intrahepatic Cholangiocarcinoma AJCC v7;   Unresectable Gallbladder Carcinoma;   Unresectable Pancreatic Carcinoma Interventions:   Biological: Durvalumab;   Drug: Guadecitabine Sponsors:   University of Southern California;   National C...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials